PUBLIC COMPANY
saveREGENERON PHARMACEUTICALS
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
- phase1Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
- phase1REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
- phase3Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
- phase3A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
- phase2Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)
- phase3A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
- phase2A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
🐶 Hiring Signal
News
- Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drugThe go-ahead for Alnylam Pharmaceuticals–licensed Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.biospace · 2d ago
- With FDA nod, Regeneron brings an RNAi drug to autoimmune diseaseThe product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.biopharma_dive · 2d ago
- J&J bets $2.2B on Ollin’s vision loss drugThe deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.biopharma_dive · 5d ago
- Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trialRegeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.biospace · 8d ago
- Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trialRegeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.fiercebiotech · 8d ago
- 10 companies hiring in New JerseyLooking for a biopharma job in New Jersey? Jobs on BioSpace increased year over year in October, and there are hundreds of open positions posted now.biospace · 9d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 11d ago
- The top 12 companies hiring in biopharma nowAverage jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.biospace · 16d ago
- Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilienceAstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.biopharma_dive · 19d ago
- Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deckRegeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…biospace · 22d ago
comments(0)
5-min edit window · permanent after that